Efficacy and Safety of Gabapentin in Treating Overactive Bladder

Inclusion Criteria:

• Ambulatory and able to use the toilet without difficulty

• History of OAB symptoms for ≥ 3 months

• An average of ≥ 8 micturitions per 24 hours and ≥ 1 urgency episode (with or withoutincontinence) per 24 hours as documented in a 3-day micturition diary

• Subjects are bothered by symptoms as reflected by OAB-questionnaire

Exclusion Criteria:

• Patient has stress or mixed incontinence

• Patient has Benign Prostatic Hyperplasia with severe lower urinary tract symptomsbased on IPSS score

• Patient has uncontrolled Diabetes Mellitus Type II Patient has Diabetes Insipidus, UTI

• Patient has history of interstitial cystitis, painful bladder syndrome, or chronicpelvic pain

• Patient has a history of stroke, seizures, or major neurological disorders

• Patient has a history of fecal incontinence and or continual urine leakage

• Patient has had surgery to correct stress urinary incontinence or pelvic organprolapse within 6 months of study start

• Patient received bladder training of electrostimulation within 2 weeks of study start

• Patient requires a catheter

• Patient is taking medications that cannot be stopped for the duration of the trialincluding certain anticholinergics or smooth muscle relaxants

• Patient began taking tricyclic antidepressants, serotonin/norepinephrine reuptakeinhibitors, calcium channel blockers, ephedrine/pseudoephedrine, or diuretic therapyless than 8 weeks before study start

• Patient has been on hormone replacement therapy for less than 12 weeks at study start

• Patient must take medication for arrhythmia, contraindicated for Solifenacin orGabapentin

• Patient has multiple and/or severe allergies to foods and drugs

• Patient regularly uses any illegal drugs